摘要
通过一系列努力,我国血浆蛋白制品和病毒相关的安全性得到显著提高,总体上已非常安全。但由于管理和技术等因素的限制,仍然残留一定的通过相关制品经血传播病毒的风险。为此,必须强调血浆蛋白制品的合理使用,严格掌握其适应证,科学确定预期疗效和相应的使用剂量,以保证血浆蛋白制品的疗效并尽可能降低患者可能面对的风险。
With systemic efforts the viral safety of human plasma derivative products in China has been significantly improved and the products are safe in general. However, there are still residual risks of transmitting blood-born viruses via the products due to the administrative and technical limitation. It is necessary to emphasize the rational use of the products and be sure that the products are only used for patients with reasonable indications and the target of therapy and dosage of the products are properly determined. Therefore, the effectiveness of the products can be ensured and the risks are avoided as much as possible.
出处
《中国执业药师》
CAS
2012年第9期37-41,共5页
China Licensed Pharmacist
关键词
血浆蛋白制品
经血传播病毒
适应证
Plasma Derivative Product
Blood-born Virus
Indications
